Brief: OliX Pharmaceuticals Doses First Patient In Clinical Trial For RNAi Therapeutic OLX10212 For Dry And Wet Age-Related Macular Degeneration
27/03/2023 13:27
March 27 (Reuters) - OliX Pharmaceuticals Inc
226950.KQ :
* OLIX PHARMACEUTICALS DOSES FIRST PATIENT IN CLINICAL TRIAL
FOR
RNAI THERAPEUTIC OLX10212 FOR DRY AND WET AGE-RELATED MACULAR
DEGENERATION
Source text for Eikon: ID:nBw3MW1gfa
Further company coverage: 226950.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on OliX Pharmaceuticals
See all newsBrief: Olix Pharmaceuticals Receives Milestone Payment From L'oreal
Brief: OliX And Lilly Enter Global Licensing Agreement For Mash And Other Cardiometabolic Indications
Brief: Olix Pharmaceuticals Commences Patient Dosing In Phase 1 Clinical Trial Of Olx75016
Brief: Olix Pharmaceuticals Receives Hrec Approval To Initiate Phase 1 Clinical Trial Of Nash And Obesity Drug
Brief: OliX Pharmaceuticals Administers First Patient In Phase 1 Clinical Study of Androgenic Alopecia Treatment